Výsledky vyhledávání - "Jayne E. Curry"

Supplementary Figure Legend from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

Autor: Nicola G. Wallis, Neil T. Thompson, John Lyons, Patrick Schöffski, Jonathan A. Fletcher, Mark Mayeda, Jennifer G. Morgan, Rachel Donsky, Meijun Zhu, Agnieszka Wozniak, Ana M. Rodriguez-Lopez, Jayne E. Curry, Thomas Van Looy, Tomoko Smyth

PDF file, 70KB.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1effe4eb85ba14ae1a71178ade9a91c
https://doi.org/10.1158/1535-7163.22498800.v1

Zobrazit plný text záznamu

Supplementary Figure 2 from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

PDF file, 289KB, Western immunoblots and their densitometric analyses showing the pharmacodynamic response of GIST430 xenograft to 22 days of AT13387, imatinib or combination treatment.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd1cebda49e8d94a1721204465a08cb
https://doi.org/10.1158/1535-7163.22498803.v1

Zobrazit plný text záznamu

Supplementary Figure 1 from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

PDF file, 56KB, Graphs showing the typical dose response of GIST882, GIST430 and GIST48 cell lines to AT13387 and imatinib.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85068f99b5a98f7424ed9d866e7ecdb7
https://doi.org/10.1158/1535-7163.22498806

Zobrazit plný text záznamu

Data from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

The majority of gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT, an HSP90 client protein. Further secondary resistance mutations within KIT limit clinical responses to tyrosine kinase inhibitors, such as imatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02c79bfd68c90607a7e4450a9897a31f
https://doi.org/10.1158/1535-7163.c.6535971

Zobrazit plný text záznamu

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders

Autor: Mark A, Dawson, Jayne E, Curry, Kelly, Barber, Philip A, Beer, Brent, Graham, John F, Lyons, Caroline J, Richardson, Mike A, Scott, Tomoko, Smyth, Matthew S, Squires, Neil T, Thompson, Anthony R, Green, Nicola G, Wallis

Publikováno v: British journal of haematology. 150(1)

Constitutive activation of Janus kinase (Jak) 2 is the most prevalent pathogenic event observed in the myeloproliferative disorders (MPD), suggesting that inhibitors of Jak2 may prove valuable in their management. Inhibition of the Aurora kinases has

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8fc2724dc097ed20fb386e226e14bf51
https://pubmed.ncbi.nlm.nih.gov/20507304

Zobrazit plný text záznamu

Akademický článek

A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.

Autor: King Chi Chan, Choi Man Ting, Pui Shan Chan, Ming Chu Lo, Kwok Wai Lo, Jayne E. Curry, Tomoko Smyth, Anne Wing Mui Lee, Wai Tong Ng, George Sai Wah Tsao, Ricky Ngok Shun Wong, Maria Li Lung, Nai Ki Mak

Publikováno v: Molecular Cancer; 2013, Vol. 12 Issue 1, p1-27, 27p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání